Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland and has exclusive IP rights until the mid-2030s. In Europe it is marketed as
Feraccru® with commercialisation led by Norgine BV and in the USA the product which benefits from NCE exclusivity until 2024 will be marketed as Accrufer®.
RT @Edison_Inv_Res: .@ShieldTx: Has kick-started 2020 by securing an out-licensing deal in China for its primary asset, #Feraccru/Accrufer.…
RT @VoxPodcast: Hardman & Co Research: Shield Therapeutics (STX): Taking on China #STX @ShieldTx https://t.co/d3gILMFRiH #voxmarkets via @v…
RT @WalbrookPR: Note issued by @HardmanandCo on @ShieldTx (AIM: #STX) today: Taking on China; https://t.co/ahhXmkildT
